{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T09:48:32Z","timestamp":1794649712932,"version":"4.9.1"},"reference-count":154,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.critrevonc.2025.104964","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T19:22:36Z","timestamp":1758828156000},"page":"104964","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Molecular insights into the role of tumor-specific endothelial cells in metastasis"],"prefix":"10.1016","volume":"216","author":[{"given":"Tahereh Zarei","family":"Taher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir Hossein","family":"Kheirkhah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Mehri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Mahmoudian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajjad","family":"Atashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8047-8754","authenticated-orcid":false,"given":"Maria","family":"Kavianpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.critrevonc.2025.104964_bib1","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1016\/j.cell.2023.03.003","article-title":"Metastasis","volume":"186","author":"Gerstberger","year":"2023","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib2","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10585-021-10120-z","article-title":"Molecular mechanisms of cancer metastasis via the lymphatic versus the blood vessels","volume":"39","author":"Leong","year":"2022","journal-title":"Clin. Exp. Metastas.."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib3","doi-asserted-by":"crossref","first-page":"91","DOI":"10.2174\/1574888X16666210622123942","article-title":"Development and clinical application of Tumor-derived exosomes in patients with cancer","volume":"17","author":"Verdi","year":"2022","journal-title":"Curr. Stem Cell Res. amp Ther."},{"issue":"1-2","key":"10.1016\/j.critrevonc.2025.104964_bib4","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.mrrev.2011.05.002","article-title":"Initial steps of metastasis: cell invasion and endothelial transmigration","volume":"728","author":"van Zijl","year":"2011","journal-title":"Mutat. Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib5","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1158\/2159-8290.CD-21-0010","article-title":"Metastasis-Initiating cells and ecosystems","volume":"11","author":"Massagu\u00e9","year":"2021","journal-title":"Cancer Discov."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104964_bib6","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41568-018-0038-z","article-title":"Every step of the way: integrins in cancer progression and metastasis","volume":"18","author":"Hamidi","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104964_bib7","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.3389\/fimmu.2024.1460437","article-title":"Finding potential targets in cell-based immunotherapy for handling the challenges of acute myeloid leukemia","volume":"15","author":"Kheirkhah","year":"2024","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.acthis.2023.152070","article-title":"The role of vascular endothelial cells in tumor metastasis","volume":"125","author":"Feng","year":"2023","journal-title":"Acta Histochem."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104964_bib9","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20184411","article-title":"Vascular endothelial cell biology: an update","volume":"20","author":"Kr\u00fcger-Genge","year":"2019","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16040816","article-title":"Circulating tumor cells: how far have we come with mining these seeds of metastasis?","volume":"16","author":"Radhakrishnan","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104964_bib11","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/mc.23354","article-title":"Amateur antigen-presenting cells in the tumor microenvironment","volume":"61","author":"Darragh","year":"2022","journal-title":"Mol. Carcinog."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib12","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1756-8722-6-61","article-title":"An evolving new paradigm: endothelial cells \u2013 conditional innate immune cells","volume":"6","author":"Mai","year":"2013","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.756334","article-title":"A new antitumor direction: Tumor-Specific endothelial cells","volume":"11","author":"Liang","year":"2021","journal-title":"Front Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2025.104964_bib14","doi-asserted-by":"crossref","first-page":"2906","DOI":"10.1182\/blood-2011-01-331694","article-title":"Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression","volume":"118","author":"Franco","year":"2011","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104964_bib15","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21072606","article-title":"The epigenetic profile of tumor endothelial cells. Effects of combined therapy with antiangiogenic and epigenetic drugs on cancer progression","volume":"21","author":"Ciesielski","year":"2020","journal-title":"Int J. Mol. Sci."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104964_bib16","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1042\/CS20200308","article-title":"Vascular toxicity associated with anti-angiogenic drugs","volume":"134","author":"Neves","year":"2020","journal-title":"Clin. Sci."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104964_bib17","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1007\/s00432-021-03701-8","article-title":"Targeting tumor vascularization: promising strategies for vascular normalization","volume":"147","author":"Zheng","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104964_bib18","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21093238","article-title":"Tumor endothelial Cell-A biological tool for translational cancer research","volume":"21","author":"Annan","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104964_bib19","doi-asserted-by":"crossref","DOI":"10.3389\/fphys.2023.1199225","article-title":"Tumour associated endothelial cells: origin, characteristics and role in metastasis and anti-angiogenic resistance","volume":"14","author":"Yao","year":"2023","journal-title":"Front Physiol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib20","first-page":"6","article-title":"Vascular endothelial growth factor (VEGF) family and the immune system: activators or inhibitors?","volume":"13","author":"Failla","year":"2025"},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104964_bib21","doi-asserted-by":"crossref","first-page":"5369","DOI":"10.7150\/ijbs.73949","article-title":"Tumor microenvironment and its implications for antitumor immunity in cholangiocarcinoma: future perspectives for novel therapies","volume":"18","author":"Cao","year":"2022","journal-title":"Int. J. Biol. Sci."},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104964_bib22","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13246226","article-title":"Insights into the role of matrix metalloproteinases in precancerous conditions and in colorectal cancer","volume":"13","author":"Pezeshkian","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104964_bib23","article-title":"Mechanisms for modulating anoikis resistance in cancer and the relevance of metabolic reprogramming","volume":"11","author":"Adeshakin","year":"2021"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104964_bib24","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jb\/mvx033","article-title":"miR-145 promoted anoikis resistance in tumor endothelial cells","volume":"162","author":"Hida","year":"2017","journal-title":"J. Biochem"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104964_bib25","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14112735","article-title":"Cancer-Induced metabolic rewiring of tumor endothelial cells","volume":"14","author":"Lidonnici","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib26","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12964-019-0478-4","article-title":"Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment","volume":"17","author":"Annan","year":"2019","journal-title":"Cell Commun. Signal"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib27","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.3892\/ol.2012.928","article-title":"Energy metabolism of cancer: glycolysis versus oxidative phosphorylation (Review)","volume":"4","author":"Zheng","year":"2012","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.critrevonc.2025.104964_bib28","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jare.2024.05.001","article-title":"Metabolic reprogramming and interventions in angiogenesis","volume":"70","author":"Liu","year":"2025","journal-title":"J. Adv. Res."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib29","doi-asserted-by":"crossref","first-page":"270","DOI":"10.4093\/dmj.2018.0101","article-title":"Role of the pyruvate dehydrogenase complex in metabolic remodeling: differential pyruvate dehydrogenase complex functions in metabolism","volume":"42","author":"Park","year":"2018","journal-title":"Diabetes Metab. J."},{"issue":"15","key":"10.1016\/j.critrevonc.2025.104964_bib30","first-page":"8616","article-title":"CD44 contributes to the regulation of MDR1 protein and doxorubicin chemoresistance in osteosarcoma","volume":"23","author":"Gerardo-Ram\u00edrez","year":"2022"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib31","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s10585-015-9755-9","article-title":"Aldehyde dehydrogenase as a marker and functional mediator of metastasis in solid tumors","volume":"33","author":"Rodriguez-Torres","year":"2016","journal-title":"Clin. Exp. Metastas.."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104964_bib32","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1158\/0008-5472.CAN-19-3791","article-title":"Chemotherapy-Induced IL8 upregulates MDR1\/ABCB1 in tumor blood vessels and results in unfavorable outcome","volume":"80","author":"Kikuchi","year":"2020","journal-title":"Cancer Res"},{"key":"10.1016\/j.critrevonc.2025.104964_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2023.101821","article-title":"Epigenetic modifications: key players in cancer heterogeneity and drug resistance","volume":"39","author":"Sadida","year":"2024","journal-title":"Transl. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104964_bib34","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1016\/j.ajpath.2011.11.035","article-title":"Heterogeneity of tumor endothelial cells: comparison between tumor endothelial cells isolated from High- and Low-Metastatic tumors","volume":"180","author":"Ohga","year":"2012","journal-title":"Am. J. Pathol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104964_bib35","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41419-023-05707-1","article-title":"Tumor malignancy by genetic transfer between cells forming cell-in-cell structures","volume":"14","author":"Wang","year":"2023","journal-title":"Cell Death Dis."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12935-020-01719-5","article-title":"The role of hypoxia in the tumor microenvironment and development of cancer stem cell: a novel approach to developing treatment","volume":"21","author":"Emami Nejad","year":"2021","journal-title":"Cancer Cell Int."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib37","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3748\/wjg.v9.i6.1144","article-title":"Qin RY. Mechanism and its regulation of tumor-induced angiogenesis","volume":"9","author":"Gupta","year":"2003","journal-title":"World J. Gastroenterol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib38","article-title":"Role of angiogenesis and its biomarkers in development of targeted tumor therapies","volume":"2024","author":"Pathak","year":"2024"},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104964_bib39","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","article-title":"Tumor angiogenesis: causes, consequences, challenges and opportunities","volume":"77","author":"Lugano","year":"2020","journal-title":"Cell Mol. Life Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104964_bib40","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10456-023-09876-7","article-title":"Pathological angiogenesis: mechanisms and therapeutic strategies","volume":"26","author":"Dudley","year":"2023","journal-title":"Angiogenesis"},{"key":"10.1016\/j.critrevonc.2025.104964_bib41","article-title":"Mechanisms of angiogenesis in tumour","volume":"14","author":"Zhang","year":"2024","journal-title":"Front. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104964_bib42","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12051172","article-title":"Inducing angiogenesis, a key step in cancer vascularization, and treatment approaches","volume":"12","author":"Saman","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.critrevonc.2025.104964_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117585","article-title":"Physiological and tumor-associated angiogenesis: key factors and therapy targeting VEGF\/VEGFR pathway","volume":"180","author":"Lorenc","year":"2024","journal-title":"Biomed. Pharmacother."},{"issue":"17","key":"10.1016\/j.critrevonc.2025.104964_bib44","first-page":"9191","article-title":"Hypoxia pathway proteins and their impact on the blood vasculature","volume":"22","author":"Rodriguez","year":"2021"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib45","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/s41392-023-01460-1","article-title":"Angiogenic signaling pathways and anti-angiogenic therapy for cancer","volume":"8","author":"Liu","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.critrevonc.2025.104964_bib46","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.3389\/fonc.2019.01370","article-title":"Role of matrix metalloproteinases in angiogenesis and cancer","volume":"9","author":"Quintero-Fabi\u00e1n","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.3389\/fonc.2020.00221","article-title":"Resistance mechanisms to Anti-angiogenic therapies in cancer","volume":"10","author":"Haibe","year":"2020","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib48","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1146\/annurev-physiol-020518-114700","article-title":"Normalizing function of tumor vessels: progress, opportunities, and challenges","volume":"81","author":"Martin","year":"2019","journal-title":"Annu Rev. Physiol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib49","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s10456-017-9562-9","article-title":"Tumor angiogenesis and vascular normalization: alternative therapeutic targets","volume":"20","author":"Viallard","year":"2017","journal-title":"Angiogenesis"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib50","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1186\/s12935-021-02408-7","article-title":"The hippo signaling pathway in leukemia: function, interaction, and carcinogenesis","volume":"21","author":"Noorbakhsh","year":"2021","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib51","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.canlet.2012.08.018","article-title":"Angiopoietins in angiogenesis","volume":"328","author":"Fagiani","year":"2013","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104964_bib52","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s10555-018-9752-y","article-title":"The roles of the COX2\/PGE2\/EP axis in therapeutic resistance","volume":"37","author":"Tong","year":"2018","journal-title":"Cancer Metastas.. Rev."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104964_bib53","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0048342","article-title":"Targeting COX-2\/PGE(2) pathway in HIPK2 knockdown cancer cells: impact on dendritic cell maturation","volume":"7","author":"Garufi","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib54","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1186\/s12964-024-01580-3","article-title":"Ephs in cancer progression: complexity and context-dependent nature in signaling, angiogenesis and immunity","volume":"22","author":"Guo","year":"2024","journal-title":"Cell Commun. Signal."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib55","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1615\/CritRevImmunol.v30.i6.30","article-title":"Endothelial cells as key determinants of the tumor microenvironment: interaction with tumor cells, extracellular matrix and immune killer cells","volume":"30","author":"Chouaib","year":"2010","journal-title":"Crit. Rev. Immunol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib56","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1158\/0008-5472.CAN-07-1589","article-title":"Hypoxia-inducible factor-1 target genes as indicators of tumor vessel response to vascular endothelial growth factor inhibition","volume":"68","author":"Dang","year":"2008","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib57","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1186\/s13046-018-0763-x","article-title":"Integrins as therapeutic targets in the organ-specific metastasis of human malignant melanoma","volume":"37","author":"Huang","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2025.104964_bib58","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2023.1110765","article-title":"JAK\/STAT pathway: extracellular signals, diseases, immunity, and therapeutic regimens","volume":"11","author":"Hu","year":"2023","journal-title":"Front Bioeng. Biotechnol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104964_bib59","doi-asserted-by":"crossref","DOI":"10.3390\/cells12050788","article-title":"Transcriptional regulation during aberrant activation of NF-\u03baB signalling in cancer","volume":"12","author":"Deka","year":"2023","journal-title":"Cells"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib60","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1002\/stem.429","article-title":"Inhibition of notch signaling in glioblastoma targets cancer stem cells via an endothelial cell intermediate","volume":"28","author":"Hovinga","year":"2010","journal-title":"Stem Cells"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104964_bib61","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/jcp.27172","article-title":"PD-1\/PD-L1 immune checkpoint: potential target for cancer therapy","volume":"234","author":"Dermani","year":"2019","journal-title":"J. Cell Physiol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104964_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.2174\/157016110790887036","article-title":"Characterization of molecular and functional alterations of tumor endothelial cells to design anti-angiogenic strategies","volume":"8","author":"Bussolati","year":"2010","journal-title":"Curr. Vasc. Pharmacol."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib63","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s40291-019-00401-5","article-title":"S1PR1 as a novel promising therapeutic target in cancer therapy","volume":"23","author":"Rostami","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.critrevonc.2025.104964_bib64","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2022.108211","article-title":"The roles of TGF-\u03b2 and VEGF pathways in the suppression of antitumor immunity in melanoma and other solid tumors","volume":"240","author":"Bu","year":"2022","journal-title":"Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib65","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1093\/jb\/mvs136","article-title":"Vascular endothelial growth factor and its receptor system: physiological functions in angiogenesis and pathological roles in various diseases","volume":"153","author":"Shibuya","year":"2012","journal-title":"J. Biochem."},{"issue":"21","key":"10.1016\/j.critrevonc.2025.104964_bib66","first-page":"5557","volume":"13","author":"Vall\u00e9e","year":"2021","journal-title":"Key Role WNT\/?Catenin Pathw. Metab. Reprogramming Cancers Normoxic Cond."},{"issue":"13","key":"10.1016\/j.critrevonc.2025.104964_bib67","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16132478","article-title":"Emerging therapeutic strategies to overcome drug resistance in cancer cells","volume":"16","author":"Garg","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/s41392-024-01885-2","article-title":"Mechanism insights and therapeutic intervention of tumor metastasis: latest developments and perspectives","volume":"9","author":"Shi","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib69","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.cell.2016.11.037","article-title":"Emerging biological principles of metastasis","volume":"168","author":"Lambert","year":"2017","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib70","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41392-024-01955-5","article-title":"Multi-stage mechanisms of tumor metastasis and therapeutic strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib71","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41392-020-0134-x","article-title":"Molecular principles of metastasis: a hallmark of cancer revisited","volume":"5","author":"Fares","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib72","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12964-023-01429-1","article-title":"Beyond the barrier: the immune-inspired pathways of tumor extravasation","volume":"22","author":"Di Russo","year":"2024","journal-title":"Cell Commun. Signal"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib73","doi-asserted-by":"crossref","first-page":"8064","DOI":"10.1038\/s41598-025-92422-w","article-title":"Cancer cells impact the microrheology of endothelial cells during physical contact or through paracrine signalling","volume":"15","author":"Kefala","year":"2025","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104964_bib74","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.devcel.2011.11.018","article-title":"Death receptors DR6 and TROY regulate brain vascular development","volume":"22","author":"Tam","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.critrevonc.2025.104964_bib75","series-title":"Methods and Protocols","first-page":"257","article-title":"Evaluation of tight junction integrity in brain endothelial cells using confocal microscopy","author":"Alluri","year":"2023"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib76","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12987-023-00418-3","article-title":"Role of interleukin-6 and interleukin-10 in morphological and functional changes of the blood-brain barrier in hypertriglyceridemia","volume":"20","author":"Barab\u00e1si","year":"2023","journal-title":"Fluids Barriers CNS"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104964_bib77","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1161\/ATVBAHA.123.319695","article-title":"Simultaneous targeting of IL-1-Signaling and IL-6-Trans-Signaling preserves human pulmonary endothelial barrier function during a cytokine Storm-Brief report","volume":"43","author":"Col\u00e1s-Algora","year":"2023","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib78","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/cen3.12730","article-title":"Concentration-dependent effects of proinflammatory cytokines on barrier function and tight junction protein expression in brain microvascular endothelial cells and the hypothermic and hyperthermic effects on tight junction protein expression","volume":"14","author":"Matsui","year":"2023","journal-title":"Clin. Exp. Neuroimmunol."},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104964_bib79","article-title":"Vascular endothelial cell injury: causes, molecular mechanisms, and treatments","volume":"6","author":"Xia","year":"2025"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104964_bib80","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25126415","article-title":"Molecular mechanisms regulating vascular endothelial permeability","volume":"25","author":"Wakasugi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104964_bib81","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/s00424-007-0212-8","article-title":"The endothelial glycocalyx: composition, functions, and visualization","volume":"454","author":"Reitsma","year":"2007","journal-title":"Pflug. Arch."},{"key":"10.1016\/j.critrevonc.2025.104964_bib82","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.trsl.2022.03.014","article-title":"Form follows function: the endothelial glycocalyx","volume":"247","author":"Suzuki","year":"2022","journal-title":"Transl. Res."},{"key":"10.1016\/j.critrevonc.2025.104964_bib83","article-title":"Update on the role of the endothelial glycocalyx in angiogenesis and vascular inflammation","volume":"9","author":"Hu","year":"2021"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib84","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13054-018-2292-6","article-title":"The glycocalyx: a novel diagnostic and therapeutic target in sepsis","volume":"23","author":"Uchimido","year":"2019","journal-title":"Crit. Care"},{"key":"10.1016\/j.critrevonc.2025.104964_bib85","doi-asserted-by":"crossref","first-page":"621","DOI":"10.3389\/fimmu.2016.00621","article-title":"The role of the tumor vasculature in the host immune response: implications for therapeutic strategies targeting the tumor microenvironment","volume":"7","author":"Hendry","year":"2016","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib86","article-title":"The mechanisms on evasion of anti-tumor immune responses in gastric cancer","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib87","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.656364","article-title":"Aspects of the tumor microenvironment involved in immune resistance and drug resistance","volume":"12","author":"Khalaf","year":"2021","journal-title":"Front Immunol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104964_bib88","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents - overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104964_bib89","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41419-023-06119-x","article-title":"Exploring the crosstalk between endothelial cells, immune cells, and immune checkpoints in the tumor microenvironment: new insights and therapeutic implications","volume":"14","author":"Fang","year":"2023","journal-title":"Cell death Dis."},{"key":"10.1016\/j.critrevonc.2025.104964_bib90","doi-asserted-by":"crossref","unstructured":"Zhu Y., Brulois K., Dinh T., Pan J., Butcher E. Tumor immune evasion abrogated by COUP-TFII reprogramming of the vasculature 2024.","DOI":"10.21203\/rs.3.rs-3957714\/v1"},{"issue":"1-2","key":"10.1016\/j.critrevonc.2025.104964_bib91","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s00281-024-01014-9","article-title":"Vascular galectins in tumor angiogenesis and cancer immunity","volume":"46","author":"Thijssen","year":"2024","journal-title":"Semin Immunopathol."},{"issue":"40","key":"10.1016\/j.critrevonc.2025.104964_bib92","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.adq7305","article-title":"Identifying metabolic limitations in the tumor microenvironment","volume":"10","author":"Cognet","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.critrevonc.2025.104964_bib93","article-title":"Tumor hypoxia regulates immune Escape\/Invasion: influence on angiogenesis and potential impact of hypoxic biomarkers on cancer therapies","volume":"11","author":"Abou Khouzam","year":"2020","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104964_bib94","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1016\/j.immuni.2021.01.012","article-title":"Chemokines and the immune response to cancer","volume":"54","author":"Ozga","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.critrevonc.2025.104964_bib95","doi-asserted-by":"crossref","first-page":"114","DOI":"10.3389\/fphys.2014.00114","article-title":"The role IL-1 in tumor-mediated angiogenesis","volume":"5","author":"Voronov","year":"2014","journal-title":"Front Physiol."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104964_bib96","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1111\/cas.14091","article-title":"Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway","volume":"110","author":"Long","year":"2019","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2025.104964_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.175586","article-title":"The role of VEGF in cancer-induced angiogenesis and research progress of drugs targeting VEGF","volume":"949","author":"Ghalehbandi","year":"2023","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.critrevonc.2025.104964_bib98","doi-asserted-by":"crossref","DOI":"10.1177\/20503121211069012","article-title":"Tumor promoting roles of IL-10, TGF-\u03b2, IL-4, and IL-35: its implications in cancer immunotherapy","volume":"10","author":"Mirlekar","year":"2022","journal-title":"SAGE Open Med"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib99","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40001-024-01711-z","article-title":"The paradoxical role of cytokines and chemokines at the tumor microenvironment: a comprehensive review","volume":"29","author":"Abdul-Rahman","year":"2024","journal-title":"Eur. J. Med Res"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib100","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.immuni.2019.03.024","article-title":"Transforming growth Factor-\u03b2 signaling in immunity and cancer","volume":"50","author":"Batlle","year":"2019","journal-title":"Immunity"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104964_bib101","doi-asserted-by":"crossref","first-page":"316","DOI":"10.37349\/etat.2023.00137","article-title":"Transforming growth factor-\u03b2 signaling: from tumor microenvironment to anticancer therapy","volume":"4","author":"Chan","year":"2023","journal-title":"Explor Target Antitumor Ther."},{"issue":"30","key":"10.1016\/j.critrevonc.2025.104964_bib102","doi-asserted-by":"crossref","first-page":"49702","DOI":"10.18632\/oncotarget.17922","article-title":"Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma","volume":"8","author":"Xue","year":"2017","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib103","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib104","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nm.3541","article-title":"Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors","volume":"20","author":"Motz","year":"2014","journal-title":"Nat. Med"},{"key":"10.1016\/j.critrevonc.2025.104964_bib105","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1367875","article-title":"Endothelial cells in tumor microenvironment: insights and perspectives","volume":"15","author":"Leone","year":"2024","journal-title":"Front Immunol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104964_bib106","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/nri.2017.49","article-title":"Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy","volume":"17","author":"Nagarsheth","year":"2017","journal-title":"Nat. Rev. Immunol."},{"issue":"18","key":"10.1016\/j.critrevonc.2025.104964_bib107","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22189804","article-title":"Chemokine-Directed tumor microenvironment modulation in cancer immunotherapy","volume":"22","author":"Bule","year":"2021","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2025.104964_bib108","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.crimmu.2021.08.002","article-title":"Tumor-infiltrating T-regulatory cells adapt to altered metabolism to promote tumor-immune escape","volume":"2","author":"Sarkar","year":"2021","journal-title":"Curr. Res Immunol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib109","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jtbi.2012.11.031","article-title":"The effect of interstitial pressure on tumor growth: coupling with the blood and lymphatic vascular systems","volume":"320","author":"Wu","year":"2013","journal-title":"J. Theor. Biol."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104964_bib110","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188792","article-title":"Interstitial fluid pressure as an emerging biomarker in solid tumors","volume":"1877","author":"Salavati","year":"2022","journal-title":"Biochimica et Biophysica Acta (BBA) Reviews Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib111","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.jare.2017.06.006","article-title":"Anti-angiogenic agents for the treatment of solid tumors: potential pathways, therapy and current strategies \u2013 a review","volume":"8","author":"Al-Abd","year":"2017","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.critrevonc.2025.104964_bib112","article-title":"Vascular normalization: a new window opened for cancer therapies","volume":"11","author":"Yang","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib113","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1291530","article-title":"Targeting vascular normalization: a promising strategy to improve immune-vascular crosstalk in cancer immunotherapy","volume":"14","author":"Qian","year":"2023","journal-title":"Front Immunol."},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104964_bib114","doi-asserted-by":"crossref","first-page":"2308","DOI":"10.1038\/s12276-023-01114-w","article-title":"Normalization of the tumor microenvironment by harnessing vascular and immune modulation to achieve enhanced cancer therapy","volume":"55","author":"Choi","year":"2023","journal-title":"Exp. Mol. Med."},{"issue":"8","key":"10.1016\/j.critrevonc.2025.104964_bib115","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.3390\/pharmaceutics15082022","article-title":"Induced vascular Normalization\u2014Can one force tumors to surrender to a better microenvironment?","volume":"15","author":"Sun","year":"2023","journal-title":"Pharmaceutics"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib116","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41392-024-01979-x","article-title":"Cold and hot tumors: from molecular mechanisms to targeted therapy","volume":"9","author":"Wu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104964_bib117","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20235819","article-title":"Targeting tumor endothelial cells with nanoparticles","volume":"20","author":"Sakurai","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104964_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2022.188701","article-title":"Directing CAR t cells towards the tumor vasculature for the treatment of solid tumors","volume":"1877","author":"Akbari","year":"2022","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib119","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1038\/nrd.2015.17","article-title":"Ten years of anti-vascular endothelial growth factor therapy","volume":"15","author":"Ferrara","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"issue":"9807","key":"10.1016\/j.critrevonc.2025.104964_bib120","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","article-title":"Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial","volume":"378","author":"Rini","year":"2011","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib121","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N. Engl. J. Med"},{"issue":"2","key":"10.1016\/j.critrevonc.2025.104964_bib122","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med"},{"issue":"9911","key":"10.1016\/j.critrevonc.2025.104964_bib123","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","article-title":"Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial","volume":"383","author":"Fuchs","year":"2014","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib124","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","article-title":"Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial","volume":"28","author":"Sternberg","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib125","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/j.eururo.2020.08.007","article-title":"Final overall survival results from a phase 3 study to compare tivozanib to sorafenib as Third- or Fourth-line therapy in subjects with metastatic renal cell carcinoma","volume":"78","author":"Pal","year":"2020","journal-title":"Eur. Urol."},{"issue":"28","key":"10.1016\/j.critrevonc.2025.104964_bib126","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","article-title":"Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen","volume":"30","author":"Van Cutsem","year":"2012","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104964_bib127","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1510016","article-title":"Cabozantinib versus everolimus in advanced Renal-Cell carcinoma","volume":"373","author":"Choueiri","year":"2015","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104964_bib128","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1056\/NEJMoa020461","article-title":"Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors","volume":"347","author":"Demetri","year":"2002","journal-title":"N. Engl. J. Med"},{"issue":"19","key":"10.1016\/j.critrevonc.2025.104964_bib129","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1200\/JCO.21.02011","article-title":"Olaparib with or without cediranib versus Platinum-Based chemotherapy in recurrent Platinum-Sensitive ovarian cancer (NRG-GY004): a randomized, Open-Label, phase III trial","volume":"40","author":"Liu","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"14","key":"10.1016\/j.critrevonc.2025.104964_bib130","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced Renal-Cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104964_bib131","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0090353","article-title":"Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGF\u03b2) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma","volume":"9","author":"Morris","year":"2014","journal-title":"PloS One"},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib132","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1186\/s12943-024-02023-w","article-title":"Regulatory mechanisms of PD-1\/PD-L1 in cancers","volume":"23","author":"Lin","year":"2024","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104964_bib133","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s10147-016-0958-0","article-title":"Basics of PD-1 in self-tolerance, infection, and cancer immunity","volume":"21","author":"Chikuma","year":"2016","journal-title":"Int J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104964_bib134","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9030675","article-title":"Combining immune checkpoint inhibitors with Anti-Angiogenic agents","volume":"9","author":"Ciciola","year":"2020","journal-title":"J. Clin. Med"},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib135","first-page":"827","article-title":"Decoding tumor angiogenesis for therapeutic advancements: mechanistic insights","volume":"12","author":"Kaur","year":"2024"},{"key":"10.1016\/j.critrevonc.2025.104964_bib136","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2020.102017","article-title":"Bevacizumab (Avastin\u00ae) in cancer treatment: a review of 15 years of clinical experience and future outlook","volume":"86","author":"Garcia","year":"2020","journal-title":"Cancer Treat. Rev."},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104964_bib137","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16050890","article-title":"Blood Vessel-Targeted therapy in colorectal cancer: current strategies and future perspectives","volume":"16","author":"Jacobsen","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104964_bib138","first-page":"1","article-title":"Revisiting VEGF\/VEGFR-2 signalling as an anticancer target and its inhibitor discovery: where are we and where should we go?","author":"Yao","year":"2025","journal-title":"J. Drug Target"},{"issue":"11","key":"10.1016\/j.critrevonc.2025.104964_bib139","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1080\/14796694.2025.2485020","article-title":"S2303: phase II\/III trial of paclitaxel + ramucirumab \u00b1 nivolumab in gastric and esophageal adenocarcinoma (PARAMUNE)","volume":"21","author":"Saeed","year":"2025","journal-title":"Future Oncol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib140","article-title":"Enhancing antitumor immunity: the role of immune checkpoint inhibitors, anti-angiogenic therapy, and macrophage reprogramming","volume":"15","author":"Zhang","year":"2025","journal-title":"Front Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2025.104964_bib141","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17091408","article-title":"Advancing cancer treatment: a review of immune checkpoint inhibitors and combination strategies","volume":"17","author":"Mc Neil","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"12","key":"10.1016\/j.critrevonc.2025.104964_bib142","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1002\/ijc.34894","article-title":"Efficacy of ramucirumab combination chemotherapy as second-line treatment in patients with advanced adenocarcinoma of the stomach or gastroesophageal junction after exposure to checkpoint inhibitors and chemotherapy as first-line therapy","volume":"154","author":"Masetti","year":"2024","journal-title":"Int J. Cancer"},{"key":"10.1016\/j.critrevonc.2025.104964_bib143","article-title":"Advances in the treatment of hepatocellular carcinoma: an overview of the current and evolving therapeutic landscape for clinicians","author":"Moris","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib144","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13045-024-01549-2","article-title":"Immunosuppressive tumor microenvironment and immunotherapy of hepatocellular carcinoma: current status and prospectives","volume":"17","author":"Shen","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib145","article-title":"Assessing hemorrhagic risks in combination therapy: implications of angiogenesis inhibitors and immune checkpoint inhibitors","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib146","article-title":"Endostatin-based anti-angiogenic therapy and immune modulation: mechanisms and synergistic potential in cancer treatment","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol."},{"key":"10.1016\/j.critrevonc.2025.104964_bib147","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.2147\/JHC.S347932","article-title":"Safety and efficacy of atezolizumab and bevacizumab combination as a first line treatment of advanced hepatocellular carcinoma","volume":"10","author":"Zanuso","year":"2023","journal-title":"J. Hepatocell. Carcinoma"},{"issue":"7","key":"10.1016\/j.critrevonc.2025.104964_bib148","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073765","article-title":"Anti-Angiogenic therapy: current challenges and future perspectives","volume":"22","author":"Lopes-Coelho","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.critrevonc.2025.104964_bib149","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1158\/1535-7163.MCT-20-0412","article-title":"Neutralization of TGF\u03b2 improves tumor immunity and reduces tumor progression in ovarian carcinoma","volume":"20","author":"Roane","year":"2021","journal-title":"Mol. Cancer Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2025.104964_bib150","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1158\/1535-7163.MCT-20-0944","article-title":"Novel TGF\u03b2 inhibitors ameliorate oral squamous cell carcinoma progression and improve the antitumor immune response of Anti-PD-L1 immunotherapy","volume":"20","author":"Ludwig","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.critrevonc.2025.104964_bib151","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2022.104380","article-title":"The difficulty in translating the preclinical success of combined TGF\u03b2 and immune checkpoint inhibition to clinical trial","volume":"86","author":"Metropulos","year":"2022","journal-title":"EBioMedicine"},{"issue":"5","key":"10.1016\/j.critrevonc.2025.104964_bib152","doi-asserted-by":"crossref","first-page":"130","DOI":"10.3892\/mmr.2025.13495","article-title":"Role of multi\u2011omics in advancing the understanding and treatment of prostate cancer (Review)","volume":"31","author":"Yan","year":"2025","journal-title":"Mol. Med Rep."},{"issue":"4","key":"10.1016\/j.critrevonc.2025.104964_bib153","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.job.2024.09.002","article-title":"STAT3 interactome predicts presence of proteins that regulate immune system in oral squamous cell carcinoma","volume":"66","author":"Chakraborty","year":"2024","journal-title":"J. Oral. Biosci."},{"issue":"1","key":"10.1016\/j.critrevonc.2025.104964_bib154","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-44329-7","article-title":"Preclinical 3D-model supports an invisibility cloak for adenoid cystic carcinoma","volume":"13","author":"Chakraborty","year":"2023","journal-title":"Sci. Rep."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500352X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S104084282500352X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,2]],"date-time":"2026-01-02T21:15:38Z","timestamp":1767388538000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S104084282500352X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":154,"alternative-id":["S104084282500352X"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104964","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular insights into the role of tumor-specific endothelial cells in metastasis","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104964","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104964"}}